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ABSTRACT: Palonosetron is a potent 5-HT3 receptor antago-
nist and an eﬀective therapeutic agent against emesis. Here we
identify the molecular determinants of compound recognition in
the receptor binding site by obtaining a high resolution structure
of palonosetron bound to an engineered acetylcholine binding
protein that mimics the 5-HT3 receptor binding site, termed 5-
HTBP, and by examining the potency of palonosetron in a range
of 5-HT3 receptors with mutated binding site residues. The
structural data indicate that palonosetron forms a tight and
eﬀective wedge in the binding pocket, made possible by its rigid
tricyclic ring structure and its interactions with binding site
residues; it adopts a binding pose that is distinct from the related antiemetics granisetron and tropisetron. The functional data
show many residues previously shown to interact with agonists and antagonists in the binding site are important for palonosetron
binding, and indicate those of particular importance are W183 (a cation−π interaction and a hydrogen bond) and Y153 (a
hydrogen bond). This information, and the availability of the structure of palonosetron bound to 5-HTBP, should aid the
development of novel and more eﬃcacious drugs that act via 5-HT3 receptors.
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The 5-HT3 receptors, like nicotinic acetylcholine (nACh),GABAA/C, and glycine receptors, are members of the Cys-
loop family of pentameric ligand-gated ion channels.1 They play
important roles in fast neurotransmission in the central and
peripheral nervous systems. 5-HT3 receptors are located
primarily in the chemoreceptor trigger zone in the area
postrema and in the gastrointestinal (GI) tract, where they have
roles in regulating gut motility and the emesis reﬂex.2
Palonosetron (Aloxi; RS 25259-197) is a second generation
5-HT3 receptor antagonist in clinical use which acts at both
central and GI sites to reduce nausea and vomiting caused by
chemotherapy, radiotherapy, or general anesthesia.3 Compared
to ﬁrst-generation 5-HT3 receptor antagonists, such as
ondansetron and granisetron, palonosetron is more potent
and has a longer half-life, making it a highly eﬀective, long-
lasting antiemetic.4,5 It has some unusual properties that have
not yet been fully explained, such as the prolonged inhibition of
5-HT3 receptors by palonosetron; this may be due to an ability
to cause receptor internalization, though an extremely slow
dissociation rate could also explain this phenomenon.6−10
Palonosetron was discovered during the investigation of
conformationally restricted analogues of granisetron.11 Con-
ﬁrming previous ﬁndings, it was shown that the orientations of
the amide carbonyl and the tertiary amine group relative to the
aromatic nucleus were critical determinants of 5-HT3 receptor
aﬃnity. The enhanced stability brought about by subsequent
cyclization of the amide group with the aromatic structure is
likely responsible for the increase in aﬃnity compared to other
5-HT3 receptor antagonists.
To probe the speciﬁc interactions of palonosetron in order to
better understand its unusual properties, we have solved the
structure of palonosetron bound to 5-HTBP, an acetylcholine
binding protein (AChBP) from Aplysia californica (Ac)
engineered to bind 5-HT and granisetron with high aﬃnity.12
This protein carries the mutations Y53W and Q55R and
displays a 2.3-fold higher aﬃnity for the 5-HT3 receptor
antagonist granisetron and a 5.8-fold higher aﬃnity for 5-HT
than the native AChBP. We have also mutated human 5-HT3
receptor residues that contribute to the ligand-binding site
(Figure 1), and characterized the potency of palonosetron in
the resulting mutant receptors following expression in HEK293
cells.
■ RESULTS AND DISCUSSION
X-ray Crystal Structure of Palonosetron-Bound 5-
HTBP. A complete diﬀraction data set was collected from a
crystal that diﬀracted to a resolution of 2.34 Å, which allowed
determination of the 3-dimensional structure of 5-HTBP in
complex with palonosetron (Table 1). The crystal belongs to
the space group P21 and the crystallographic unit cell has the
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following dimensions: 72.21 Å (a), 137.05 Å (b), 131.25 Å (c),
90° (α), 93.78° (β), and 90° (γ) and contains two pentamers
per asymmetric unit.
Palonosetron Interactions in 5-HTBP. The data show
that palonosetron could be built into the electron density at 7
out of 10 orthosteric binding sites. Each molecule is surrounded
by predominantly aromatic and hydrophobic residues, includ-
ing Y91, W145, Y186 and Y193 on the principal binding face,
and W53, R55, V106, M114, and I116 on the complementary
face (Figure 2A). The protonated quinuclidine N of
palonosetron is within cation-π interaction distance of W145
(W183 in the 5-HT3 receptor), and there is a hydrogen bond
between the protonated N of palonosetron and the backbone
carbonyl of this residue. The near-planar tricyclic ring ﬁts in a
narrow pocket formed by the complementary face residues
(mainly M114 and I116) and loop C of the principal face
(Figure 2A). This location of palonosetron is similar to the
observed binding location of the well-studied 5-HT3 receptor
antagonist granisetron (Figure 2B), and also to the location
predicted from experimental data for another antagonist
ondansetron.12,13 This location is also supported by computa-
tional studies, although one study docking palonosetron into
the 5-HT3 receptor suggested two binding sites, one in the
orthosteric pocket and one below it; subsequent experimental
data from mutant receptors, however, did not support this
second binding site, and indicated that the eﬀects of
palonosetron are all manifest via the orthosteric binding
pocket10.14
There are, however, some interesting diﬀerences between the
palonosetron and granisetron structures. Interactions with
Figure 1. Alignment of 5-HTBP, AChBP, and the extracellular domain of the human 5-HT3A receptor subunit showing the approximate location of
the binding loops. The residues mutated in this study are highlighted in blue and magenta, and the residues that diﬀer between 5-HTBP and AChBP
are in yellow.
Table 1
5HTBP+palonosetron
crystallographic statistics
beamline ID23-2 (ESRF)
wavelength (Å) 0.873
space group P21
a,b,c (Å) 72.21, 137.05, 131.25
β (deg) 93.78
resolution limits (Å) 47.34−2.34 (2.47−2.34)
Rmerge (%) 11.9 (84.5)
Rmeas (%) 13.6 (95.6)
⟨I/σ⟩ 8.9 (1.6)
CC1/2 (%) 99.2 (59.8)
multiplicity 4.5 (4.4)
completeness (%) 98.8 (94.5)
total number of reﬂections 476 641 (65 507)
number unique reﬂections 106 052 (14 741)
reﬁnement and model statistics
Rwork (%) 22.42
Rfree (%) 25.18
rmsd bond distance (Å) 0.0111
rmsd bond angle (deg) 1.691
Ramachandran analysis
outliers (%) 0.0
favored (%) 99.06
molprobity score 0.96 (100th percentile)
Figure 2. (A) 5-HTBP binding pocket showing the orientation of
palonosetron and nearby residues. The protein backbone is shown in
light blue ribbon presentation and side chains as ball and sticks.
Palonosetron is shown as transparent spheres. Yellow is used for
carbon, red for oxygen and blue for nitrogen. The corresponding 5-
HT3 receptor residues are in parentheses. (B, C) Similar presentations
for the granisetron bound 5HTBP structure (pdb code 2YME) and
tropisetron bound AChBP structure (pdb code 2WNC). (D) Relative
binding poses of palonosetron (yellow), granisetron (green), and
tropisetron (magenta) after superposition of the binding protein
structures. The position relative to W145 is shown and the dashed line
represents a hydrogen bond.
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water appear to be important for granisetron binding, where the
structure suggested the oxygen of the amide bond may be
involved in a hydrogen bonding network with ﬁve water
molecules and Y193 (Y234 in the 5-HT3 receptor),
12 but such a
water network is not present in the palonosetron bound
structure (Figure 2). Furthermore, rather than the structures
overlapping, as might be expected from the common
pharmacophore, they are rotated relative to each other (Figure
3). Thus, in the case of palonosetron the tricyclic ring system is
tilted upward and centered relative to the complementary face
residue M114 (Q151 in 5-HT3) (Figure 2A). In contrast,
granisetron is in a more downward position, in which the
indazole moiety interacts with the complementary face residue
R55 (R92 in 5-HT3), forming a cation-π interaction as
previously described12 (Figure 2B). Despite these diﬀerences
in orientation between palonosetron and granisetron the
positively charged nitrogen atoms are in nearly identical
positions. A ligand binding pose very similar to granisetron
was described in the cocrystal structure of Ac-AChBP with
tropisetron (Figure 2C),15 which is also used as an antiemetic
and acts as a mixed antagonist for 5-HT3 and a partial agonist
for the α7 nicotinic acetylcholine receptor.16 It is possible that
the diﬀerent binding pose for palonosetron compared to
granisetron and tropisetron (Figure 2D) could also explain
some of the pharmacological diﬀerences between palonosetron
and the other -setrons.
Palonosetron Interactions at the Orthosteric Binding
Site. The aﬃnities of 5-HT and granisetron at 5HTBP are
considerably lower than when bound to 5-HT3 receptors (e.g.,
∼100 fold diﬀerence in Ki for granisetron), but nevertheless the
critical elements of recognition in this protein are supported by
many diﬀerent studies.12 We do not have a Ki value for
palonosetron, so to test if the orientation of palonosetron
observed in the structure reﬂects binding to the 5-HT3
receptor, substitutions of the human 5-HT3 receptor residues
equivalent to those within 5 Å of bound palonosetron were
made, and inhibition of function by palonosetron was explored
using membrane potential sensitive dye-loaded HEK293 cells in
a Flexstation. Typical FlexStation responses are shown in
Figure 4A, and an example concentration-inhibition curve from
WT receptors is shown in Figure 4B. Palonosetron inhibition
constants for WT and functional mutants are in Table 2. A
number of mutants (L184A, F226A, M228C, Y234A, Y234S,
W90A, Y141A, Y143A, Y143F, and Q151N) resulted in low or
no responses with 5-HT; some or all of these are likely to be
important for palonosetron binding, as has been found for
other 5-HT3 receptor ligands.
17,18
A plot of mutant receptor fold change in pEC50 compared to
WT/fold change in pKi compared to WT (Figure 5) is
consistent with both ligands binding to the same site, although
reveals some interesting diﬀerences in the importance of
various residues. Those showing the most increased potency of
palonosetron compared to 5-HT are N128A, N128Q and
Y143S (>1.5 in Figure 5), consistent with their locations close
to palonosetron. The data with N128A reﬂect both an increase
in potency of palonosetron and a decrease in potency of 5-HT,
the former possibly due to increased space in the binding site
with a smaller residue, while the latter could be due to loss of a
hydrogen bond which was revealed between the equivalent
residue and 5-HT in the 5-HTBP structure.12 Both these
proposals are consistent with data from N128Q, which only
show a decrease in potency of 5-HT. Data from Y143S reﬂects
both an increase in potency for palonosetron and a decrease in
potency for 5-HT, consistent with possible hydrophobic
interactions of this residue with both 5-HT (unfavorable) and
palonosetron (favorable).
The receptors showing the most decreased potency of
palonosetron compared to 5-HT are those with W183A and
Y153S substitutions. The data from W183A reveal a decrease in
both 5-HT and palonosetron potency, but this is greater in the
latter. W183 forms a cation−π interaction with palonosetron
both in the 5-HTBP structure and in the 5-HT3 receptor. This
is consistent with previous studies: W183 forms a cation-π
interaction with 5-HT, granisetron and ondansetron in the 5-
HT3 receptor, and the equivalent loop B aromatic residue also
forms cation-π interactions in some other Cys-loop receptors
(e.g GABAC and nACh).
12,13,19 There is also a hydrogen bond
with the backbone O in both 5-HT (2.7 Å distant) and
Figure 3. Superimposition of palonosetron (sticks) and granisetron
(wireframe) as found in the crystal structures (palonosetron, this
study; granisetron, 2YME) showing their diﬀerent orientations in the
binding site. (B) is a 90° rotation of the ﬁgure in (A).
Figure 4. (A) Typical traces from HEK cells transfected with WT 5-
HT3 receptor cDNA, loaded with membrane potential dye, incubated
with palonosetron at the concentrations shown, and stimulated at 20 s
with 1 μM 5-HT. F = arbitrary ﬂuorescent units. (B) Typical
concentration−inhibition curve for palonosetron constructed from
FlexStation responses to WT 5-HT3 receptors. Data = mean ± SEM, n
= 4.
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palonosetron (2.5 Å distant). As hydrogen bonds show a fairly
steep distance dependence, such that only a slight shift is
needed to strengthen or weaken a hydrogen bond, while
cation−π interactions are much less sensitive to distance, we
consider it likely that this hydrogen bond is more important for
palonosetron than for 5-HT binding. We speculate that the lack
of other hydrogen bonds between palonosetron and residues in
the binding pocket makes this one more signiﬁcant: 5-HT is
predicted to have other hydrogen bonds but palonosetron is
not.
The R92A mutation reveals an interesting diﬀerence between
the eﬀects of palonosetron and granisetron on the 5-HT3
receptor. While no signiﬁcant change in binding aﬃnity was
observed with palonosetron binding to R92A receptors, there
was a reduction in binding aﬃnity for granisetron.18,20 This
may be due to the cation−π interaction R92 forms with the
indazole portion of granisetron, which is apparent from both
the 5-HTBP structural data and unnatural amino acid studies.12
Such an interaction is not present in the palonosetron−5-
HTBP structure as R92 is too far from palonosetron; the
distance between the εN of R55 (R92) and the center of the
indazole ring of granisetron structure is 3.6 Å,12 compared to an
equivalent distance of 7.1 Å in the palonosetron structure; here
the isoquinoline ring of palonosetron is higher up in the
binding site than the indazole ring of granisetron (Figure 2A,B).
Table 2. Palonosetron Inhibition Constants for WT and Functional Mutantsa
loop residue mutants pKi ± SEM (M) Ki (nM) n 5-HT pEC50 (M)
b EC50 (μM) n
WT 9.76 ± 0.11 0.17 8 6.51 ± 0.03 0.30 5
A N128 N128A 10.75 ± 0.17c 0.018 6 5.47 ± 0.10c 3.4 4
N128Q 9.60 ± 0.10 0.25 6 4.53 ± 0.02c 29 4
B W183 W183A 5.13 ± 0.14c 7400 8 3.88 ± 0.05c 130 4
W183Y 7.51 ± 0.19c 31 8 4.60 ± 0.03c 25 5
B L184 L184A NR 6
L184I 9.90 ± 0.20 0.13 5 5.56 ± 0.05c 2.7 4
C F226 F226A SR 6
F226Y 9.68 ± 0.22 0.21 4 5.72 ± 0.06c 1.9 7
C M228 M228A 9.02 ± 0.27c 0.96 6 5.03 ± 0.04c 9.3 4
M228C NR 6
C E229 E229A 10.31 ± 0.30 0.049 6 5.63 ± 0.04c 2.3 6
E229D 10.00 ± 0.07 0.10 6 6.58 ± 0.05 0.26 3
C Y234 Y234A NR 6
Y234F 10.35 ± 0.10 0.045 8 5.89 ± 0.03c 1.3 4
Y234S NR 6
D W90 W90A NR 6
W90Y 9.58 ± 0.10 0.26 10 5.66 ± 0.05c 2.2 5
D R92 R92A 9.29 ± 0.12 0.51 4 6.06 ± 0.04c 0.87 4
R92Q 8.31 ± 0.09c 4.9 8 4.82 ± 0.04c 15 4
D Y94 Y94A 9.59 ± 0.05 0.26 8 7.24 ± 0.03c 0.06 5
Y94F 9.00 ± 0.13c 1.0 8 6.84 ± 0.04 0.15 6
Y94S 10.13 ± 0.17 0.074 6 7.03 ± 0.06c 0.09 6
S114 S114A 9.26 ± 0.29 0.55 4 6.31 ± 0.05 0.49 7
S114T 9.96 ± 0.05 0.11 4 5.87 ± 0.27c 1.4 3
E Y141 Y141A NR 6
Y141F 10.10 ± 0.07 0.079 4 6.83 ± 0.03 0.15 3
E Y143 Y143A NR 6
Y143F SR 4
Y143S 10.51 ± 0.07 0.031 4 4.35 ± 0.03c 45 3
E Q151 Q151A 10.21 ± 0.21 0.062 6 6.13 ± 0.06 0.74 4
Q151N 10.43 ± 0.14 0.042 3 6.34 ± 0.03 0.47 3
E Y153 Y153A 8.31 ± 0.08c 4.9 3 4.73 ± 0.03c 19 3
Y153F 8.40 ± 0.12c 3.9 8 5.54 ± 0.03c 2.9 3
Y153S 5.66 ± 0.09c 2200 4 5.32 ± 0.06c 4.8 3
aData = mean ± SEM. bData from ref 17. cSigniﬁcantly diﬀerent (p < 0.05) to WT 5-HT3A receptors. NR = no response at 100 mM 5-HT; SR =
responses too small to obtain parameters.
Figure 5. Plot of fold change in pEC50 compared to WT/fold change
in pKi compared to WT (relative potency) showing which mutations
have stronger eﬀects on 5-HT (<1) or palonosetron (>1). *Those
discussed in the text.
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The largest diﬀerence we observed in the functional data
between palonosetron and 5-HT was for the Y153S mutant
receptor (Figure 5) and is due to a much greater decrease of
potency for palonosetron compared to 5-HT. This is not due to
loss of the aromatic group, as Y153A mutant receptors have a
similar palonosetron Ki to those containing Y153F (both ∼10-
fold greater than WT), consistent with data obtained with
granisetron.18,22,23 We therefore speculate that there is an
interaction between the side chain of Ser and another residue,
or with the ligand itself, which results in less energetically
favorable antagonist binding. The equivalent residue is an
isoleucine (I116) in 5-HTBP, so the role of this residue in the
5-HT3 receptor is diﬃcult to predict. However, other studies
provide some guidance: Data from unnatural amino acid
mutageneses indicate a hydrogen bond between the −OH of
Y153 and 5-HT, consistent with a role of this residue in agonist
binding,17,21 and a similar interaction has been proposed with
granisetron. It is therefore feasible that Y153 could form a
hydrogen bond with the amide carbonyl of palonosetron.
Indeed the precision of the distance and angles of this oxygen
and the quinuclidine N with Y153 and W183, respectively
could provide an explanation as to why these functional groups
are crucial for the high aﬃnity binding of palonosetron.11
Another residue that results in diﬀerent eﬀects for 5-HT and
palonosetron when mutated is Y94 in loop D, as substitutions
here to Ala or Ser enhance 5-HT EC50s but have no eﬀect on
palonosetron Ki values. We speculate that a bulky residue facing
into the binding pocket may have a deleterious eﬀect on
agonist-induced conformational changes, which are not
required for antagonists. We also observed mutations of
N128 in Loop A and Y143S in loop E have distinct eﬀects
on 5-HT and palonosetron potencies at the functional level,
consistent with diﬀerent structures of the binding pocket in
agonist and antagonist bound receptors.
In addition to the speciﬁc residue interactions, the structural
data provide a further explanation for the eﬃcacy of
palonosetron, as its large surface area and planarity deﬁned
by the rigid tricyclic ring provides an opportunity for multiple
aromatic and other hydrophobic interactions, which drive a
highly eﬀective wedge between loop C and the complementary
face of the receptor (Figure 6).
■ CONCLUSIONS
Our structural data showing the orientation of palonosetron in
a 5-HT3 receptor binding site mimic, combined with functional
data in the 5-HT3 receptor, provide an explanation for the high
aﬃnity and long-lived actions of this compound. These are
likely due to speciﬁc interactions formed with binding site
residues, and its location as a tight and eﬀective wedge in the
binding pocket, made possible by its tricyclic ring structure.
This information, and the availability of the structure of
palonosetron bound to 5-HTBP, should aid the development of
novel even more potent and eﬃcacious drugs that act via 5-HT3
receptors.
■ METHODS
Protein Expression and Crystallization. 5-HTBP (mutant D2)
was expressed and puriﬁed as previously described.12 Puriﬁed protein
was concentrated to 6 mg/mL and a solution of palonosetron in water
was added at a ﬁnal concentration of 1 mM. Crystallizations screens
were setup with a Mosquito crystallization robot (TTP Labtech).
Crystals were obtained under a condition containing 200 mM sodium
citrate, 100 mM bis tris propane pH 8.5, and 20% (w/v) PEG3350.
Crystals were cryoprotected by adding glycerol in 5% (w/v)
increments up to a concentration of 30% (w/v) and immersed in
liquid nitrogen. X-ray diﬀraction data were collected at the ID23−2
beamline of the European Synchrotron Radiation Facility (ESRF,
Grenoble). Reﬂections were integrated with XDS24 and scaled in
SCALA in the CCP4 suite.25 The structure was solved using
MOLREP25 and the unliganded 5HTBP structure as a search model
(pdb code 2yme). Structure building was done in Coot26 and structure
reﬁnement was done in Phenix reﬁne.27 A ﬁnal polishing reﬁnement
was done in PDB REDO.28 Structure validation was done with
Molprobity.29 Figures were prepared with PyMOL (Schrödinger).
Mutagenesis. All mutant human 5-HT3 receptors were created
using QuikChange mutagenesis (Agilent).
Cell Culture. Human embryonic kidney (HEK) 293 cells were
maintained on 90 mm tissue culture plates at 37 °C and 7% CO2 in a
humidiﬁed atmosphere. They were cultured in Dulbecco’s Modiﬁed
Eagle’s Medium/Nutrient Mix F12 (1:1) with GlutaMAX I media
(Life Technologies, Paisley, UK) containing 10% HyClone fetal calf
serum (GE Healthcare). For FlexStation studies, cells were transfected
using polyethylenimine (PEI; Polysciences): 30 μL PEI (1 mg/mL), 5
μL cDNA (1 mg/mL; subcloned into pcDNA3.1), and 1 mL DMEM
were incubated for 10 min at room temperature, added dropwise to a
70−90% conﬂuent plate, and incubated for 2 days. Cells were then
transferred to poly-L-lysine (Cultrex)-coated 96-well plates and
allowed to adhere overnight before use.
FlexStation Analysis. The methods were as described pre-
viously.17 In brief, ﬂuorescent membrane potential dye (Membrane
Potential Blue kit, Molecular Devices) was diluted in Flex buﬀer (10
mM HEPES, 115 mM NaCl, 1 mM KCl, 1 mM CaCl2, 1 mM MgCl2,
and 10 mM glucose, pH 7.4) and added to each well of cells. The cells
were incubated at 37 °C for 45 min with the dye and palonosetron
(Alomone laboratories, Israel) and then ﬂuorescence measured in a
FlexStation (Molecular Devices) at 2 s intervals for 200 s. 5-HT
(Sigma) was added to each well after 20 s. Data were normalized to
the maximum ΔF. 5-HT concentration−response data17 and
palonosetron concentration-inhibition data were analyzed using
Prism (GraphPad Software Inc.) using the Leﬀ and Dougall
modiﬁcation of the Cheng-Prusoﬀ equation.30
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